
    
      Participants who complete the 48-week Treatment Period will be offered the opportunity to
      continue their treatment in a 48-week Extension Period that will offer additional time for
      evaluation of long-term efficacy and safety of ALXN1840. There will be no liver biopsies
      during the Extension Period.
    
  